As I mentioned I was already aware of this, but the upcoming Phase 1 trial bisantrene will be used as a cardioprotective agent where the dosing schedule is determined by the existing doxorubicin schedule. We will be exploring how to best use bisantrene as an anticancer agent in other trials. There is not just one way to use bisantrene.
- Forums
- ASX - By Stock
- CPACS: Research, Results, Market Comparisons, and Valuations
As I mentioned I was already aware of this, but the upcoming...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.57 |
Change
0.010(0.64%) |
Mkt cap ! $267.5M |
Open | High | Low | Value | Volume |
$1.58 | $1.64 | $1.55 | $90.52K | 56.87K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 279 | $1.59 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.60 | 957 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 279 | 1.585 |
2 | 2550 | 1.575 |
2 | 6535 | 1.570 |
2 | 2250 | 1.565 |
1 | 1050 | 1.560 |
Price($) | Vol. | No. |
---|---|---|
1.595 | 957 | 2 |
1.600 | 1000 | 1 |
1.610 | 3974 | 2 |
1.615 | 1050 | 1 |
1.630 | 300 | 1 |
Last trade - 12.20pm 15/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online